Last reviewed · How we verify
Liposomal bupivacaine left injection
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Local anesthesia for infiltration, nerve block, and regional anesthesia procedures.
At a glance
| Generic name | Liposomal bupivacaine left injection |
|---|---|
| Also known as | Exparel Left |
| Sponsor | Prisma Health-Upstate |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine, an amide-type local anesthetic, works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby preventing depolarization and blocking pain signal transmission. The liposomal formulation encapsulates bupivacaine in lipid vesicles, which extends the drug's duration of action and allows for prolonged local anesthesia at the injection site. This formulation reduces systemic toxicity while maintaining efficacy for regional anesthesia.
Approved indications
- Local anesthesia for infiltration, nerve block, and regional anesthesia procedures
Common side effects
- Injection site pain or discomfort
- Transient neurological symptoms
- Hypotension
- Bradycardia
- Systemic toxicity (rare)
Key clinical trials
- Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions (PHASE4)
- Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial (PHASE4)
- Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures (PHASE4)
- EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries (PHASE4)
- TAP-patients With Robotic Assisted Lap Prostatectomy (PHASE4)
- EXPAREL Post-tonsillectomy Clinical Trial (PHASE4)
- Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery (PHASE4)
- Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal bupivacaine left injection CI brief — competitive landscape report
- Liposomal bupivacaine left injection updates RSS · CI watch RSS
- Prisma Health-Upstate portfolio CI